J. Feng

3.2k total citations
71 papers, 1.0k citations indexed

About

J. Feng is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, J. Feng has authored 71 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 43 papers in Pulmonary and Respiratory Medicine and 16 papers in Surgery. Recurrent topics in J. Feng's work include Lung Cancer Treatments and Mutations (24 papers), Colorectal Cancer Treatments and Studies (14 papers) and Gastric Cancer Management and Outcomes (11 papers). J. Feng is often cited by papers focused on Lung Cancer Treatments and Mutations (24 papers), Colorectal Cancer Treatments and Studies (14 papers) and Gastric Cancer Management and Outcomes (11 papers). J. Feng collaborates with scholars based in China, United States and South Korea. J. Feng's co-authors include Ying Huang, Jin Liu, Shun Lü, Xiao Ke, W. Li, Zhengwen Ning, Xiaoting Hong, Z. Shen, Xianping Lu and Li Yu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Molecular Sciences.

In The Last Decade

J. Feng

64 papers receiving 1000 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Feng China	15	660	425	291	221	175	71	1.0k
Keisuke Aiba Japan	15	500 0.8×	284 0.7×	194 0.7×	333 1.5×	149 0.9×	71	992
J.L. Geiger United States	16	681 1.0×	243 0.6×	235 0.8×	469 2.1×	129 0.7×	92	1.3k
Hiromichi Yamane Japan	15	491 0.7×	339 0.8×	183 0.6×	112 0.5×	206 1.2×	85	865
Laura Visa Spain	15	662 1.0×	417 1.0×	180 0.6×	262 1.2×	220 1.3×	37	1.0k
Dylan J. Martini United States	17	729 1.1×	422 1.0×	166 0.6×	186 0.8×	52 0.3×	68	1.0k
A. Misino Italy	11	755 1.1×	368 0.9×	134 0.5×	133 0.6×	106 0.6×	25	983
A Fanucchi Italy	24	420 0.6×	181 0.4×	267 0.9×	390 1.8×	100 0.6×	64	1.6k
L. Leong United States	16	648 1.0×	241 0.6×	199 0.7×	238 1.1×	144 0.8×	41	1.0k
L. Austin Doyle United States	12	407 0.6×	200 0.5×	338 1.2×	236 1.1×	247 1.4×	35	922
Mona Fouad Egypt	16	638 1.0×	278 0.7×	157 0.5×	95 0.4×	70 0.4×	32	896

Countries citing papers authored by J. Feng

Since Specialization

Citations

This map shows the geographic impact of J. Feng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Feng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Feng more than expected).

Fields of papers citing papers by J. Feng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Feng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Feng. The network helps show where J. Feng may publish in the future.

Co-authorship network of co-authors of J. Feng

This figure shows the co-authorship network connecting the top 25 collaborators of J. Feng. A scholar is included among the top collaborators of J. Feng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Feng. J. Feng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jiang, Zhi‐Yun, Jingyi Ding, Xue Guo, et al.. (2025). Enrichment effects of vegetation patches on soil water content depend on precipitation and vegetation conditions: A global meta-analysis. Journal of Hydrology. 661. 133590–133590.

Zheng, Bin, Kan Liu, J. Feng, et al.. (2025). GAMT facilitates tumor progression via inhibiting p53 in clear cell renal cell carcinoma. Biology Direct. 20(1). 43–43.

Zheng, Bin, et al.. (2024). Identification of metabolic dysregulation and biomarkers for clear cell renal cell carcinoma. Clinical and Translational Medicine. 14(12). e70142–e70142. 3 indexed citations

Zhang, Yu, Hegen Li, Xuliang Li, et al.. (2024). Camptothecin-loaded and IR780-doped polydopamine nanomedicine used for multifunctional chemo-photothermal-photodynamic therapy for lung cancer. Journal of Drug Delivery Science and Technology. 97. 105657–105657. 7 indexed citations

Feng, J., Zhijie Zhang, Xiwang Liu, et al.. (2024). Platelet Proteomics and Tissue Metabolomics Investigation for the Mechanism of Aspirin Eugenol Ester on Preventive Thrombosis Mechanism in a Rat Thrombosis Model. International Journal of Molecular Sciences. 25(19). 10747–10747. 1 indexed citations

Li, Qianqian, Xiaozhong Guo, J. Feng, et al.. (2022). Risk Factors for Esophageal Collateral Veins in Cirrhosis with and without Previous Endoscopic Esophageal Variceal Therapy. Canadian Journal of Gastroenterology and Hepatology. 2022. 1–13. 3 indexed citations

Feng, J., et al.. (2020). Double Agent: SPDEF Gene with Both Oncogenic and Tumor-Suppressor Functions in Breast Cancer. SHILAP Revista de lepidopterología. 1 indexed citations

Guo, Xiaozhong, J. Feng, Zhaohui Bai, et al.. (2020). Gastrointestinal Bleeding due to Pancreatic Disease-Related Portal Hypertension. Gastroenterology Research and Practice. 2020. 1–9. 14 indexed citations

Jiang, Zefei, Takahiro Nakayama, Seigo Nakamura, et al.. (2020). LBA 1 Baseline characteristics of patients from Asia enrolled in monarchE, evaluating abemaciclib in high risk early breast cancer. Annals of Oncology. 31. S1241–S1241. 1 indexed citations

10.

Zhou, C.Z., J. Feng, Shenglin Ma, et al.. (2020). 1262P Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) ≥1%: KEYNOTE-033. Annals of Oncology. 31. S816–S816. 6 indexed citations

11.

Zheng, Heng, Yong Zhang, Yulu Zhan, et al.. (2019). Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma. SHILAP Revista de lepidopterología. 1 indexed citations

12.

Guo, Ye, Yifeng Luo, Q. Zhang, et al.. (2018). First-line cetuximab plus cisplatin and fluorouracil vs cisplatin and fluorouracil in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: The randomized, phase III CHANGE-2 trial. Annals of Oncology. 29. ix176–ix176. 1 indexed citations

13.

Jiang, Zefei, W. Li, Xin Hu, et al.. (2018). Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer. Annals of Oncology. 29. viii709–viii709. 4 indexed citations

14.

Shi, Yuankai, Q. Zhang, Xiao-Feng Han, et al.. (2018). First china-manufactured proposed rituximab biosimilar met primary efficacy and safety endpoints in CD20-positive diffuse large B-cell lymphoma (generics). Annals of Oncology. 29. ix88–ix88. 3 indexed citations

15.

Zhang, L., Shun Lü, J. Feng, et al.. (2017). A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Annals of Oncology. 29(2). 452–458. 66 indexed citations

16.

Feng, J., Bo Shen, Li Deng, et al.. (2017). Real world data about clinical efficacy and safety of apatinib in the treatment of advanced gastric cancer. Annals of Oncology. 28. v237–v237. 2 indexed citations

17.

Shi, Yue, Mei Dong, Xiaoting Hong, et al.. (2015). Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Annals of Oncology. 26(8). 1766–1771. 263 indexed citations

18.

Shen, Lin, Zhihao Lü, Tianshu Liu, et al.. (2015). 144O Comparison of efficacy and safety of paclitaxel and capecitabine followed by capecitabine as maintenance therapy versus cisplatin and capecitabine therapy for advanced gastric cancer: a multicentre, randomised, active-controlled phase III study. Annals of Oncology. 26. ix42–ix42. 1 indexed citations

19.

Feng, J., et al.. (2013). Preoperative platelet count in esophageal squamous cell carcinoma: is it a prognostic factor?. Langenbeck s Archives of Surgery. 398(8). 1115–1122. 24 indexed citations

20.

Wei, Jia, Zhengyun Zou, Xiaoping Qian, et al.. (2008). ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. British Journal of Cancer. 98(8). 1398–1402. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact